SCHEMBL18646362

SCHEMBL18646362

CSc1cc(Cn2cc(C(=O)N[C@H]3CCCC[C@@H]3O)c3c(F)cccc32)ccn1

nearest known ligand 0.80

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 20/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18646363 0.89 CHRM1 (0.63) CHRM1
SCHEMBL20979770 0.89 CHRM1 (1.00) CHRM1
SCHEMBL18645651 0.89 CHRM1 (1.00) CHRM1
SCHEMBL18646266 0.89 CHRM1 (0.80) CHRM1
SCHEMBL20481663 0.88 CHRM1 (1.00) CHRM1
SCHEMBL20481675 0.85 CHRM1 (0.81) CHRM1
SCHEMBL17924305 0.84 CHRM1 (0.77) CHRM1
SCHEMBL16610136 0.83 CHRM1 (0.76) CHRM1
SCHEMBL16610131 0.83 CHRM1 (0.76) CHRM1
SCHEMBL16610088 0.83 CHRM1 (0.77) CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3347349-B1 FLUOROINDOLE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS SUVEN LIFE SCIENCES LTD (IN) 2019-09-18 EP claimed
US-10294217-B2 Fluoroindole derivatives as muscarinic M1 receptor positive allosteric modulators SUVEN LIFE SCIENCES LIMITED (IN) 2019-05-21 US claimed
US-20180244655-A1 Fluoroindole Derivatives as Muscarinic M1 Receptor Positive Allosteric Modulators SUVEN LIFE SCIENCES LIMITED (IN) 2018-08-30 US claimed
EP-3347349-B1 FLUOROINDOLE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS SUVEN LIFE SCIENCES LTD (IN) 2019-09-18 EP disclosed
EP-3347349-B1 FLUOROINDOLE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS SUVEN LIFE SCIENCES LTD (IN) 2019-09-18 EP disclosed
US-10294217-B2 Fluoroindole derivatives as muscarinic M1 receptor positive allosteric modulators SUVEN LIFE SCIENCES LIMITED (IN) 2019-05-21 US disclosed
US-10294217-B2 Fluoroindole derivatives as muscarinic M1 receptor positive allosteric modulators SUVEN LIFE SCIENCES LIMITED (IN) 2019-05-21 US disclosed
US-20180244655-A1 Fluoroindole Derivatives as Muscarinic M1 Receptor Positive Allosteric Modulators SUVEN LIFE SCIENCES LIMITED (IN) 2018-08-30 US disclosed
WO-2017042643-A1 FLUOROINDOLE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS SUVEN LIFE SCIENCES LIMITED (IN) 2017-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10294217-B2 Fluoroindole derivatives as muscarinic M1 receptor positive allosteric modulators CHRM1, CHRM2, CHRM3 CHRM1 1/4885
US-20180244655-A1 Fluoroindole Derivatives as Muscarinic M1 Receptor Positive Allosteric Modulators CHRM1, CHRM2, CHRM3 CHRM1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.